Biofourmis

American unicorn Biofourmis leverages cutting-edge technologies to facilitate interactions between patients and care teams.

This approach leads to optimized medical treatments and increased patient monitoring. The company is committed to promoting digital therapy using artificial intelligence and machine learning.

Using sensors placed on patients, Biofourmis collects crucial data for analyzing the effects of treatments and predicting possible complications. Its tools are adaptable to a variety of medical fields, including monitoring treatments for heart failure, oncology, acute coronary syndrome and chronic pain.

Although the company is based in Boston, founder Kuldeep Singh Rajput remains true to his Singaporean roots. "I am an active member of the healthcare innovation ecosystem and entrepreneurial community in Singapore. I'm also a researcher at the National University of Singapore, where I focus on bioelectronic medicines," he says.

In 2022, Biofourmis recorded sales of $71 million, registering impressive growth of 263% over the previous year.